Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business ...
Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, ...
Progress Reports Fourth Quarter 2024 and Full Year Results
Annualized Recurring Revenue grew 46% year-over-year2024 Cash Flow from Operations $212 million vs. $174 million last year, 22% growthShareFile ...